儿童二期人工晶状体植入囊袋内与睫状沟植入的安全性和有效性:多中心单盲随机对照试验
该研究为多中心、单盲、随访10年的随机对照试验方案,计划在中国4家眼科诊所连续纳入至少286只眼(约228名参与者),随机分组行二期囊袋内或睫状沟人工晶状体植入。主要结局为人工晶状体偏位和青光眼相关不良事件发生率,旨在为儿童无晶状体眼治疗临床指南提供高质量证据。
要点
- 首个评估儿童二期人工晶状体囊袋内与睫状沟植入安全性和有效性的随机对照试验。
- 主要结局为人工晶状体偏位和青光眼相关不良事件发生率,随访10年。
- 计划纳入至少286只眼,来自中国4家眼科诊所,连续入组符合条件的患者。
核心结论
- 据作者所知,本研究是首个评估儿童无晶状体眼二期人工晶状体植入安全性和有效性的随机对照试验,结果将为儿童无晶状体眼治疗的临床指南提供高质量证据。
研究设计与样本
- 多中心、单盲随机对照试验方案,随访10年,在中国4家眼科诊所开展。
- 计划连续纳入至少286只眼(假设75%的参与者有两只研究眼,约228名参与者)。
- 符合条件的两只眼参与者接受相同治疗,随机分配至二期囊袋内人工晶状体植入或二期睫状沟人工晶状体植入。
- 主要结局为人工晶状体偏位和青光眼相关不良事件发生率,次要结局包括其他不良事件发生率、人工晶状体倾斜、视力和眼屈光力。
- 主要和次要结局分析基于意向性治疗和符合方案分析,统计方法包括卡方检验或Fisher精确检验、混合模型和广义估计方程(GEE)模型、Kaplan-Meier生存曲线。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of pediatric cataract remains challenging because of the extremely high incidence of postoperative adverse events (AEs), especially the AEs related to the locations of secondary implanted intraocular lens (IOL). There are two common locations for secondary IOL implantation in pediatric aphakic eyes: ciliary sulcus or in-the-bag implantation. However, there are currently no large, prospective studies comparing complication rates and visual prognosis of in-the-bag versus ciliarysulcus secondary IOL implantation in pediatric patients. Whether or how much secondary in-the-bag IOL implantation benefits the pediatric patients more than sulcus implantation and deserves to be performed routinely by surgeons remains to be elucidated. Here, we describe the protocol of a randomized controlled trial (RCT) designed to evaluate the safety and efficacy of two approaches of IOL implantation in pediatric aphakia. METHODS: The study is a multicenter, single-blinded RCT with 10 years of follow-up. Overall, a minimum of 286 eyes (approximately 228 participants assuming 75% have two study eyes) will be recruited. This study will be carried out in four eye clinics across China. Consecutive eligible patients are randomized to undergo either secondary in-the-bag IOL implantation or secondary sulcus IOL implantation. Participants with two eyes eligible will receive the same treatment. The primary outcomes are IOL decentration and the incidence of glaucoma-related AEs. The secondary outcomes include the incidence of other AEs, IOL tilt, visual acuity, and ocular refractive power. Analysis of the primary and secondary outcomes is to be based on the intention-to-treat and per-protocol analysis. Statistical analyses will include the χ2 test or Fisher's exact test for the primary outcome, mixed model and generalized estimated equation (GEE) model for the secondary outcome, Kaplan-Meier survival curves for the cumulative probability of glaucoma-related AEs over time in each group. DISCUSSION: To the best of our knowledge, this study is the first RCT to evaluate the safety and efficacy of secondary IOL implantation in pediatric aphakia. The results will provide high-quality evidence for the clinical guidelines for the treatment of pediatric aphakia. TRIAL REGISTRATION: ClinicalTrials.gov NCT05136950. Registered on 1 November 2021.
引用
- Zou Y, Jin L, Qu B, et al. Safety and efficacy in pediatric secondary intraocular lens implantation, in-the-bag versus sulcus implantation: a multicenter, single-blinded randomized controlled trial. Trials. 2023. PMID: 37296411. doi:10.1186/s13063-023-07411-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。